Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
World Journal of Urology
Erschienen in: World Journal of Urology 1/2016

01.01.2016 | Topic Paper

Treatment of muscle invasive bladder cancer in the elderly: navigating the trade-offs of risk and benefit

verfasst von: Noam A. VanderWalde, Michelle T. Chi, Arti Hurria, Matthew D. Galsky, Matthew E. Nielsen

Erschienen in: World Journal of Urology | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Despite the fact that bladder cancer patients have the highest median age of any type of cancer, older patients with muscle invasion are often under-treated.

Methods

In this review, we report the most up to date literature on the patterns of care and treatment of older patients with muscle invasive bladder cancer. Data on under-treatment, geriatric principles, cystectomy, perioperative chemotherapy, and bladder preservation for older patients are presented and analyzed.

Conclusion

Chronologic age should not exclude patients from curative-intent therapy. Functional age as determined by geriatric assessments and multidisciplinary evaluation can help clinicians decide on the best course of treatment for individual patients. Cystectomy, perioperative chemotherapy, and curative-intent bladder preservation are reasonable options in healthy older adults. Observation should be limited to patients with extremely poor performance status and very limited life expectancy.
Literatur
1.
American Cancer Society (2014) Cancer treatment and survivorship facts and figures 2014–2015. American Cancer Society, Atlanta
2.
3.
Gray PJ, Fedewa SA, Shipley WU et al (2013) Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol 63(5):823–829CrossRefPubMed
4.
Fedeli U, Fedewa SA, Ward EM (2011) Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J Urol 185(1):72–78CrossRefPubMed
5.
Smith AB, Deal AM, Woods ME et al (2014) Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base. BJU Int 114(5):719–726CrossRefPubMed
6.
Smith BD, Smith GL, Hurria A et al (2009) Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27(17):2758–2765CrossRefPubMed
7.
Langford AT, Resnicow K, Dimond EP et al (2014) Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, and reasons for decline among patients at sites in the National Cancer Institute’s Community Cancer Centers Program. Cancer 120(6):877–884CrossRefPubMedPubMedCentral
8.
9.
10.
Stuck AE, Siu AL, Wieland GD et al (1993) Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 342(8878):1032–1036CrossRefPubMed
11.
Hurria A, Gupta S, Zauderer M et al (2005) Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 104(9):1998–2005CrossRefPubMed
12.
Hurria A, Cirrincione CT, Muss HB et al (2011) Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol 29(10):1290–1296CrossRefPubMedPubMedCentral
13.
Hurria A, Togawa K, Mohile SG et al (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29(25):3457–3465CrossRefPubMedPubMedCentral
14.
Audisio RA, Pope D, Ramesh HS et al (2008) Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol 65(2):156–163CrossRefPubMed
15.
Caillet P, Canoui-Poitrine F, Vouriot J et al (2011) Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol 29(27):3636–3642CrossRefPubMed
16.
Extermann M, Aapro M, Bernabei R et al (2005) Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 55(3):241–252CrossRefPubMed
17.
Brandtstadter J, Renner G (1990) Tenacious goal pursuit and flexible goal adjustment: explication and age-related analysis of assimilative and accommodative strategies of coping. Psychol Aging 5(1):58–67CrossRefPubMed
18.
19.
Bellmunt J, Orsola A, Leow JJ et al (2014) Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(Suppl. 3):iii40–iii48CrossRefPubMed
20.
Booth CM, Siemens DR, Li G et al (2014) Curative therapy for bladder cancer in routine clinical practice: a population-based outcomes study. Clin Oncol (R Coll Radiol) 26(8):506–514CrossRef
21.
Farnham SB, Cookson MS, Alberts G et al (2004) Benefit of radical cystectomy in the elderly patient with significant co-morbidities. Urol Oncol 22(3):178–181CrossRefPubMed
22.
Chang SS, Alberts G, Cookson MS et al (2001) Radical cystectomy is safe in elderly patients at high risk. J Urol 166(3):938–941CrossRefPubMed
23.
Donat SM, Siegrist T, Cronin A et al (2010) Radical cystectomy in octogenarians—Does morbidity outweigh the potential survival benefits? J Urol 183(6):2171–2177CrossRefPubMed
24.
Morgan TM, Keegan KA, Barocas DA et al (2011) Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy. J Urol 186(3):829–834CrossRefPubMed
25.
Nielsen ME, Mallin K, Weaver MA et al (2014) Association of hospital volume with conditional 90-day mortality after cystectomy: an analysis of the National Cancer Data Base. BJU Int 114(1):46–55CrossRefPubMedPubMedCentral
26.
Zakaria AS, Santos F, Tanguay S et al (2015) Radical cystectomy in patients over 80 years old in Quebec: a population-based study of outcomes. J Surg Oncol 111(7):917–922CrossRefPubMed
27.
28.
Advanced Bladder Cancer Meta-analysis Collaboration (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48(2):202–205 (discussion 205–206) CrossRef
29.
Grossman HB, Natale RB, Tangen CM et al (2003) Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349(9):859–866CrossRefPubMed
30.
Lee FC, Harris W, Cheng HH et al (2013) Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer. Adv Urol 2013:317190PubMedPubMedCentral
31.
Galsky MD, Pal SK, Chowdhury S et al (2015) Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer 121(15):2586–2593CrossRefPubMed
32.
Zaid HB, Patel SG, Stimson CJ et al (2014) Trends in the utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer: results from the National Cancer Database. Urology 83(1):75–80CrossRefPubMed
33.
34.
Dash A, Galsky MD, Vickers AJ et al (2006) Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107(3):506–513CrossRefPubMed
35.
Bamias A, Efstathiou E, Moulopoulos LA et al (2005) The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. Ann Oncol 16(2):307–313CrossRefPubMed
36.
Galsky MD, Krege S, Lin CC et al (2014) Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. Urol Oncol 32(1):30.e15–30.e21CrossRef
37.
Freiha F, Reese J, Torti FM (1996) A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155(2):495–499 (discussion 499–500) CrossRefPubMed
38.
Cognetti F, Ruggeri EM, Felici A et al (2012) Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann Oncol 23(3):695–700CrossRefPubMed
39.
Sternberg CN, Skoneczna I, Kerst JM et al (2015) Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N + M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol 16(1):76–86CrossRefPubMed
40.
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration (2005) Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol 48(2):189–199 (discussion 199–201) CrossRef
41.
Svatek RS, Shariat SF, Lasky RE et al (2010) The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin Cancer Res 16(17):4461–4467CrossRefPubMed
42.
Galsky MD, Stensland K, Moshier EL et al (2015) Comparative effectiveness of adjuvant chemotherapy (AC) versus observation in patients with ≥pT3 and/or pN+ bladder cancer (BCa). J Clin Oncol 33(Suppl. 7):292
43.
Galsky MD, Chen GJ, Oh WK et al (2012) Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol 23(2):406–410CrossRefPubMed
44.
Mertens LS, Meijer RP, Kerst JM et al (2012) Carboplatin based induction chemotherapy for nonorgan confined bladder cancer—a reasonable alternative for cisplatin unfit patients? J Urol 188(4):1108–1113CrossRefPubMed
45.
Hussain SA, Palmer DH, Lloyd B et al (2012) A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncol Lett 3(4):855–859PubMedPubMedCentral
46.
Kaufman DS, Shipley WU, Griffin PP et al (1993) Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med 329(19):1377–1382CrossRefPubMed
47.
Shipley WU, Winter KA, Kaufman DS et al (1998) Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 16(11):3576–3583PubMed
48.
Kaufman DS, Winter KA, Shipley WU et al (2000) The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 5(6):471–476CrossRefPubMed
49.
Hagan MP, Winter KA, Kaufman DS et al (2003) RTOG 97-06: initial report of a phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 57(3):665–672CrossRefPubMed
50.
Kaufman DS, Winter KA, Shipley WU et al (2009) Phase I–II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 73(4):833–837CrossRefPubMed
51.
Mitin T, Hunt D, Shipley WU et al (2013) Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol 14(9):863–872CrossRefPubMedPubMedCentral
52.
Mak RH, Hunt D, Shipley WU et al (2014) Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 32(34):3801–3809CrossRefPubMedPubMedCentral
53.
Efstathiou JA, Bae K, Shipley WU et al (2009) Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol 27(25):4055–4061CrossRefPubMedPubMedCentral
54.
Zietman AL, Sacco D, Skowronski U et al (2003) Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol 170(5):1772–1776CrossRefPubMed
55.
Lagrange JL, Bascoul-Mollevi C, Geoffrois L et al (2011) Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015). Int J Radiat Oncol Biol Phys 79(1):172–178CrossRefPubMed
56.
Shipley WU, Prout GR Jr, Einstein AB et al (1987) Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 258(7):931–935CrossRefPubMed
57.
Hussain MH, Glass TR, Forman J et al (2001) Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study. J Urol 165(1):56–60 (discussion 60–61) CrossRefPubMed
58.
James ND, Hussain SA, Hall E et al (2012) Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 366(16):1477–1488CrossRefPubMed
59.
Herchenhorn D, Dienstmann R, Peixoto FA et al (2007) Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma. Int Braz J Urol 33(5):630–638 (discussion 638) CrossRefPubMed
60.
Kitamura H, Tsukamoto T, Shibata T et al (2014) Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209. Ann Oncol 25(6):1192–1198CrossRefPubMed
Metadaten
Titel
Treatment of muscle invasive bladder cancer in the elderly: navigating the trade-offs of risk and benefit
verfasst von
Noam A. VanderWalde
Michelle T. Chi
Arti Hurria
Matthew D. Galsky
Matthew E. Nielsen
Publikationsdatum
01.01.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 1/2016
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-015-1708-z

Weitere Artikel der Ausgabe 1/2016

World Journal of Urology 1/2016 Zur Ausgabe

Original Article

Accuracy of cognitive MRI-targeted biopsy in hitting prostate cancer-positive regions of interest

Original Article

Minilaparoscopy in urology: initial results after 32 cases

Topic Paper

Balancing risk and benefit of extended pelvic lymph node dissection in patients undergoing radical cystectomy

Topic Paper

Open radical cystectomy: still the gold standard for muscle invasive bladder cancer

Topic Paper

The state and potential of social media in bladder cancer

Topic Paper

Ileal conduit: standard urinary diversion for elderly patients undergoing radical cystectomy

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise